Earth-abundant metal (EAM) catalysis can have profound
impact in
the pharmaceutical industry in terms of sustainability and cost improvements
from replacing precious metals like palladium as well as harnessing
the differential reactivity of first-row metals that allows for novel
transformations to enable more efficient routes to clinical candidates.
The strategy for building these capabilities within the process group
at Bristol Myers Squibb is described herein, with the general plan
of building a reaction screening platform, demonstrating scalability,
and increasing mechanistic understanding of the reaction and catalyst
activation. The development of catalytic transformations utilizing
nickel, cobalt, and iron is described while highlighting the importance
of collaboration with internal and external groups to advance EAM
catalysis and impact our portfolio. The challenges and benefits of
working with first-row transition metals, including metrics for the
implementation of EAM catalysis, such as cost, process mass intensity,
and commercial availability of catalysts and ligands, are discussed.